Diabetes mellitus, particularly type 2 diabetes mellitus (T2DM), represents a rapidly expanding global health challenge with substantial public health and economic consequences. Recent advances in antidiabetic therapy-including dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dual GIP/GLP-1 receptor agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors-have transformed diabetes management by providing benefits beyond glycemic control, such as cardiovascular and renal protection, weight reduction, and improved quality of life. As the therapeutic landscape becomes increasingly complex and patient-centered, ensuring the safe and effective use of these agents in real-world settings has emerged as a key concern for pharmacoepidemiology and pharmacovigilance. Community pharmacists, as highly accessible healthcare professionals, play an expanding role in diabetes care through medication optimization, patient education, adherence support, and monitoring of adverse drug reactions in primary care. Evidence from systematic reviews and meta-analyses indicates that pharmacist-led interventions improve glycemic outcomes, enhance self-care behaviors, and facilitate the appropriate adoption of contemporary antidiabetic therapies. This narrative review synthesizes current evidence on novel pharmacological treatments for T2DM and examines the evolving contribution of community pharmacists in translating therapeutic innovation into routine practice. Barriers to implementation and future perspectives for integrating pharmacist-led services into diabetes management and pharmacovigilance frameworks are also discussed.